As shown in Figure 5D, significant upregulation of COLEC12 was observed in 9 tumors, including liver hepatocellular carcinoma (LIHC) (tumor: - 2.15 ± 2.15 ± 2.14, normal tissue: 4.08 ± 1.08 ± 1.77, p = 7.6e-22) and PAAD (tumor: 1.95 ± 1.85, normal tissue: - 0.95 ± 1.85, normal: - 0.84 ± 1.7e-36), and significant downregulation was detected in 20 tumors, including BC (tumor: 2.59± 1.56, normal tissue: 3.29 ± 0.90, p=3.0e-14) and colon adenocarcinoma (COAD)/rectal adenocarcinoma (READ) (tumor: -0.35 ± 1.91, normal tissue: 2.25 ± 1.74, p=2.4e-70). This evidence concerns the gene COLEC12 and breast cancer.